A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR plus MBC) and metastatic ovarian cancer (MOC)

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR plus MBC) and metastatic ovarian cancer (MOC)

【24h】

A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR plus MBC) and metastatic ovarian cancer (MOC)

机译：CDK4 / 6抑制剂Ribociclib与激素受体阳性转移性乳腺癌（HR加MBC）和转移性卵巢癌（MOC）组合的CDK4 / 6抑制剂核酸核酸核苷酸的第1B期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词
入库时间 2022-08-20 01:55:28

相似文献

外文文献
中文文献
专利

1. A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR plus MBC) and metastatic ovarian cancer (MOC) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：CDK4 / 6抑制剂Ribociclib与激素受体阳性转移性乳腺癌（HR加MBC）和转移性卵巢癌（MOC）组合的CDK4 / 6抑制剂核酸核酸核苷酸的第1B期研究
2. A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：在CDK4 / 6抑制剂的进展后，在激素受体阳性（HR +）/ Her2-转移性乳腺癌（MBC）中的帕尔巴昔米菌（Palbo）和EveSeTane（Eve）和exemestane（EXE）研究（CDK4 / 6i ）：II期研究的结果
3. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：患有激素受体阳性（HR +）/ Her2-转移乳腺癌（MBC）患者内在和基因依赖性激酶4/6抑制剂（CDK4 / 6i）的基因组和获得性抗性的基因组景观
4. Locoregional hyperthermia in combination with chemotherapy for metastatic breast cancer patients: The Mammatherm- trial [C] . J.K. Jueckstock, B. Eberhardt, H.L. Sommer World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：局部热疗联合化疗治疗转移性乳腺癌患者：Mammatherm-试验
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial [O] . Kerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, 2017

机译：氟维司群单独或与硼替佐米合用治疗对芳香化酶抑制剂耐药的激素受体阳性转移性乳腺癌的随机II期试验：纽约癌症协会试验
7. Correction: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer [O] . 2018

机译：矫正：墨西哥乳酸，CDK4和CDK6抑制剂的II期研究，难治性HR + / HER2-转移性乳腺癌的患者
8. Transcription Factor Stat5, A Novel Therapeutic Protein, Inhibits Metastatic Potential and Invasive Characteristics of Human Breast Cancer Cells [R] . Sultan, A. S. 2004

机译：转录因子stat5，一种新型治疗蛋白，抑制转移潜能和人乳腺癌细胞的侵袭特征

A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR plus MBC) and metastatic ovarian cancer (MOC)

著录项

相似文献

相关主题

期刊订阅